Partial Volume Correction Increases the Sensitivity of 18F-Florbetapir-Positron Emission Tomography for the Detection of Early Stage Amyloidosis

dc.contributor.authorTeipel, Stefan J.
dc.contributor.authorDyrba, Martin
dc.contributor.authorVergallo, Andrea
dc.contributor.authorLista, Simone
dc.contributor.authorHabert, Marie Odile
dc.contributor.authorPotier, Marie-Claude
dc.contributor.authorLamari, Foudil
dc.contributor.authorDubois, Bruno
dc.contributor.authorHampel, Harald
dc.contributor.authorGrothe, Michel J.
dc.contributor.authoraffiliation[Teipel, Stefan J.] German Ctr Neurodegenerat Dis DZNE, Rostock, Germany
dc.contributor.authoraffiliation[Dyrba, Martin] German Ctr Neurodegenerat Dis DZNE, Rostock, Germany
dc.contributor.authoraffiliation[Grothe, Michel J.] German Ctr Neurodegenerat Dis DZNE, Rostock, Germany
dc.contributor.authoraffiliation[Teipel, Stefan J.] Univ Med Rostock, Dept Psychosomat Med, Rostock, Germany
dc.contributor.authoraffiliation[Vergallo, Andrea] Sorbonne Univ, Pitie Salpetriere Hosp, AP HP, GRC 21,Alzheimer Precis Med APM, Blvd Hop, Paris, France
dc.contributor.authoraffiliation[Lista, Simone] Sorbonne Univ, Pitie Salpetriere Hosp, AP HP, GRC 21,Alzheimer Precis Med APM, Blvd Hop, Paris, France
dc.contributor.authoraffiliation[Hampel, Harald] Sorbonne Univ, Pitie Salpetriere Hosp, AP HP, GRC 21,Alzheimer Precis Med APM, Blvd Hop, Paris, France
dc.contributor.authoraffiliation[Lista, Simone] CNRS UMR 7225, Brain & Spine Inst ICM, INSERM U 1127, Blvd Hop, Paris, France
dc.contributor.authoraffiliation[Lista, Simone] Hop La Pitie Salpetriere, AP HP, Dept Neurol, Inst Memory & Alzheimers Dis IM2A, Blvd Hop, Paris, France
dc.contributor.authoraffiliation[Dubois, Bruno] Hop La Pitie Salpetriere, AP HP, Dept Neurol, Inst Memory & Alzheimers Dis IM2A, Blvd Hop, Paris, France
dc.contributor.authoraffiliation[Habert, Marie Odile] Sorbonne Univ, Lab Imagerie Biomed, CNRS, INSERM, Paris, France
dc.contributor.authoraffiliation[Habert, Marie Odile] Hop La Pitie Salpetriere, AP HP, Dept Nucl Med, Paris, France
dc.contributor.authoraffiliation[Habert, Marie Odile] Ctr Acquisit & Traitement Images CATI Platform, Paris, France
dc.contributor.authoraffiliation[Potier, Marie-Claude] UPMC, Hop Pitie Salpetriere, ICM Inst Cerveau & Moelle Epiniere, CNRS UMR 7225,INSERM U1127, 47 Bd Hop, Paris, France
dc.contributor.authoraffiliation[Lamari, Foudil] Hop La Pitie Salpetriere, UF Biochim Malad Neurometab, Serv Biochim Metab, Paris, France
dc.contributor.authoraffiliation[Grothe, Michel J.] Hosp Univ Virgen del Rocio CSIC Univ Sevilla, Unidad Trastornos Movimiento, Serv Neurol & Neurofisiol Clin, Inst Biomed Sevilla, Seville, Spain
dc.contributor.funder"Miguel Servet" program
dc.contributor.funderInstituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER)
dc.contributor.funderAlzheimer's Disease Neuroimaging Initiative (ADNI)
dc.contributor.funderNational Institutes of Health
dc.contributor.funderDOD ADNI (Department of Defense)
dc.contributor.funderNational Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering
dc.contributor.funderAlzheimer's Association
dc.contributor.funderAlzheimer's Drug Discovery Foundation
dc.contributor.funderAraclon Biotech
dc.contributor.funderBioClinica, Inc.
dc.contributor.funderBiogen Idec Inc.
dc.contributor.funderBristol-Myers Squibb Company
dc.contributor.funderEisai Inc.
dc.contributor.funderElan Pharmaceuticals, Inc.
dc.contributor.funderEli Lilly and Company
dc.contributor.funderEuroImmun
dc.contributor.funderF. Hoffmann-La Roche Ltd.
dc.contributor.funderGenentech, Inc.
dc.contributor.funderFujirebio
dc.contributor.funderGE Healthcare
dc.contributor.funderIXICO Ltd.
dc.contributor.funderJanssen Alzheimer Immunotherapy Research & Development, LLC.
dc.contributor.funderJohnson & Johnson Pharmaceutical Research & Development LLC.
dc.contributor.funderMedpace, Inc.
dc.contributor.funderMerck Co., Inc.
dc.contributor.funderMeso Scale Diagnostics, LLC.
dc.contributor.funderNeuroRx Research
dc.contributor.funderNeurotrack Technologies
dc.contributor.funderNovartis Pharmaceuticals Corporation
dc.contributor.funderPfizer Inc.
dc.contributor.funderPiramal Imaging
dc.contributor.funderServier
dc.contributor.funderSynarc Inc.
dc.contributor.funderTakeda Pharmaceutical Company
dc.contributor.funderCanadian Institutes of Health Research
dc.contributor.funderInvestissement d'Avenir
dc.contributor.funderFoundation Plan-Alzheimer
dc.contributor.funderFrench Plan Alzheimer
dc.contributor.funderAVID/Lilly
dc.date.accessioned2025-01-07T16:31:10Z
dc.date.available2025-01-07T16:31:10Z
dc.date.issued2021-12-22
dc.description.abstractPurpose: To test whether correcting for unspecific signal from the cerebral white matter increases the sensitivity of amyloid-PET for early stages of cerebral amyloidosis.Methods: We analyzed 18F-Florbetapir-PET and cerebrospinal fluid (CSF) A beta 42 data from 600 older individuals enrolled in the Alzheimer's Disease Neuroimaging Initiative (ADNI), including people with normal cognition, mild cognitive impairment (MCI), and Alzheimer's disease (AD) dementia. We determined whether three compartmental partial volume correction (PVC-3), explicitly modeling signal spill-in from white matter, significantly improved the association of CSF A beta 42 levels with global 18F-Florbetapir-PET values compared with standard processing without PVC (non-PVC) and a widely used two-compartmental PVC method (PVC-2). In additional voxel-wise analyses, we determined the sensitivity of PVC-3 compared with non-PVC and PVC-2 for detecting early regional amyloid build-up as modeled by decreasing CSF A beta 42 levels. For replication, we included an independent sample of 43 older individuals with subjective memory complaints from the INveStIGation of AlzHeimer's PredicTors cohort (INSIGHT-preAD study).Results: In the ADNI sample, PVC-3 18F-Florbetapir-PET values normalized to whole cerebellum signal showed significantly stronger associations with CSF A beta 42 levels than non-PVC or PVC-2, particularly in the lower range of amyloid levels. These effects were replicated in the INSIGHT-preAD sample. PVC-3 18F-Florbetapir-PET data detected regional amyloid build-up already at higher (less abnormal) CSF A beta 42 levels than non-PVC or PVC-2 data.Conclusion: A PVC approach that explicitly models unspecific white matter binding improves the sensitivity of amyloid-PET for identifying the earliest stages of cerebral amyloid pathology which has implications for future primary prevention trials.
dc.identifier.doi10.3389/fnagi.2021.748198
dc.identifier.issn1663-4365
dc.identifier.pmid35002673
dc.identifier.unpaywallURLhttps://www.frontiersin.org/articles/10.3389/fnagi.2021.748198/pdf
dc.identifier.urihttps://hdl.handle.net/10668/27833
dc.identifier.wosID742042800001
dc.journal.titleFrontiers in aging neuroscience
dc.journal.titleabbreviationFront. aging neurosci.
dc.language.isoen
dc.organizationInstituto de Investigación Biomédica de Sevilla (IBIS)
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.publisherFrontiers media sa
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectamyloid PET
dc.subjectcerebral amyloidosis
dc.subjectpartial volume effect
dc.subjectcerebrospinal fluid
dc.subjectAlzheimer's disease
dc.subjectearly detection
dc.subjectVoxel-based analysis
dc.subjectCerebrospinal-fluid
dc.subjectQuantitative-analysis
dc.subjectWhite-matter
dc.subjectBeta
dc.subjectBrain
dc.subjectQuantification
dc.subjectIndividuals
dc.subjectValidation
dc.subjectDeposition
dc.titlePartial Volume Correction Increases the Sensitivity of 18F-Florbetapir-Positron Emission Tomography for the Detection of Early Stage Amyloidosis
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number13
dc.wostypeArticle

Files